Literature DB >> 23330815

Treatment goals for moderate to severe psoriasis: an Australian consensus.

Christopher Baker1, Alexandra Mack, Alan Cooper, Gayle Fischer, Stephen Shumack, Shireen Sidhu, H Peter Soyer, Peter Soyer, Jason Wu, Jonathan Chan, Peter Nash, Morton Rawlin, Barbara Radulski, Peter Foley.   

Abstract

BACKGROUND/
OBJECTIVES: The high incidence of comorbidities in patients with psoriasis, significant impact on quality of life and patients' dissatisfaction with treatment led a European group to develop a consensus position on psoriasis treatment goals. There is an evident need for similar treatment goals in Australia. The aim of this project was to develop Australian treatment goals that reflect the local environment.
METHODS: A panel of 12 representatives was drawn from across Australia consisting of nine dermatologists and a rheumatologist, a dermatology nurse and a general practitioner (GP)/dermatology trainee. The group met on three occasions between September 2011 and March 2012. The panel undertook a literature review and critically examined available evidence-based treatment goals. A questionnaire relating to psoriasis assessment and specific treatment outcomes was developed. Following discussion and debate, recommended treatment goals for psoriasis patients in Australia were determined.
RESULTS: The panel agreed by consensus on recommended psoriasis treatment goals in the Australian environment. There was recognition that in addition to psoriasis area severity index (PASI) assessment, a quality of life assessment was highly relevant in determining psoriasis severity and treatment outcome. Mild psoriasis was defined as PASI ≤ 10 and a dermatology life quality index (DLQI) ≤ 10, with moderate to severe psoriasis defined as PASI > 10 and/or DLQI > 10. The presence of certain definedclinical features would elevate a patient's classification from mild to moderate/severe. The target for treatment was defined as a maintained change in PASI ≥ 75% improvement and DLQI ≤ 5. These largely concurred with the European treatment goals. A flow chart for psoriasis management in Australia based on outcome measures was developed.
CONCLUSIONS: There is a need to identify and articulate treatment goals for psoriasis. Assessment of psoriasis severity requires both physical scoring (PASI) and consideration of quality of life measures (DLQI). Identification of treatment goals will guide clinicians in treatment decision-making, enhance the availability and appropriate use of therapies and increase patient satisfaction with their care.
© 2013 The Authors. Australasian Journal of Dermatology © 2013 The Australasian College of Dermatologists.

Entities:  

Mesh:

Year:  2013        PMID: 23330815     DOI: 10.1111/ajd.12014

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  11 in total

1.  Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis.

Authors:  S Indhumathi; Medha Rajappa; Laxmisha Chandrashekar; P H Ananthanarayanan; D M Thappa; V S Negi
Journal:  Eur J Clin Pharmacol       Date:  2017-04-25       Impact factor: 2.953

2.  Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting.

Authors:  Junko Takeshita; Kristina Callis Duffin; Daniel B Shin; Gerald G Krueger; Andrew D Robertson; Andrea B Troxel; Abby S Van Voorhees; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2014-06-11       Impact factor: 11.527

3.  Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies.

Authors:  Marjolein De Bruin-Weller; Tilo Biedermann; Robert Bissonnette; Mette Deleuran; Peter Foley; Giampiero Girolomoni; Jana Hercogová; Chih-Ho Hong; Norito Katoh; Andrew E Pink; Marie-Aleth Richard; Stephen Shumack; Juan F Silvestre; Stephan Weidinger
Journal:  Acta Derm Venereol       Date:  2021-02-17       Impact factor: 3.875

4.  Oral granulated Chinese herbal medicine (YXBCM01) plus topical calcipotriol for psoriasis vulgaris: study protocol for a double-blind, randomized placebo controlled trial.

Authors:  Shefton Parker; Anthony Lin Zhang; Claire Shuiqing Zhang; Greg Goodman; Zehuai Wen; Chuanjian Lu; Charlie Changlie Xue
Journal:  Trials       Date:  2014-12-19       Impact factor: 2.279

5.  Nail involvement in adult patients with plaque-type psoriasis: prevalence and clinical features.

Authors:  Karen Regina Rosso Schons; André Avelino Costa Beber; Maristela de Oliveira Beck; Odirlei André Monticielo
Journal:  An Bras Dermatol       Date:  2015-06-01       Impact factor: 1.896

Review 6.  Emerging Roles of Redox-Mediated Angiogenesis and Oxidative Stress in Dermatoses.

Authors:  Dehai Xian; Jing Song; Lingyu Yang; Xia Xiong; Rui Lai; Jianqiao Zhong
Journal:  Oxid Med Cell Longev       Date:  2019-04-16       Impact factor: 6.543

7.  Cost-Effectiveness Analysis of Psoriasis Treatment Modalities in Malaysia.

Authors:  Nor Azmaniza Azizam; Aniza Ismail; Saperi Sulong; Norazirah Md Nor
Journal:  Int J Health Policy Manag       Date:  2019-07-01

8.  Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations.

Authors:  Paolo Gisondi; Marina Talamonti; Andrea Chiricozzi; Stefano Piaserico; Paolo Amerio; Anna Balato; Federico Bardazzi; Piergiacomo Calzavara Pinton; Anna Campanati; Angelo Cattaneo; Paolo Dapavo; Clara De Simone; Valentina Dini; Maria C Fargnoli; Maria L Flori; Marco Galluzzo; Claudio Guarneri; Claudia Lasagni; Francesco Loconsole; Ada Lo Schiavo; Piergiorgio Malagoli; Giovanna Malara; Santo R Mercuri; Maria L Musumeci; Luigi Naldi; Manuela Papini; Aurora Parodi; Concetta Potenza; Francesca Prignano; Franco Rongioletti; Luca Stingeni; Rossana Tiberio; Marina Venturini; Luca Bianchi; Antonio Costanzo; Francesco Cusano; Giampiero Girolomoni; Anna M Offidani; Ketty Peris
Journal:  Dermatol Ther (Heidelb)       Date:  2021-01-11

9.  Providing Guidance for Patients With Moderate-to-Severe Psoriasis Who Are Candidates for Biologic Therapy: Role of the Nurse Practitioner and Physician Assistant.

Authors:  Lakshi M Aldredge; Melodie S Young
Journal:  J Dermatol Nurses Assoc       Date:  2016-02-12

Review 10.  An evolution in switching therapy for psoriasis patients who fail to meet treatment goals.

Authors:  Francisco Kerdel; Martin Zaiac
Journal:  Dermatol Ther       Date:  2015-08-10       Impact factor: 2.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.